Cytoplasmic PML: From molecular regulation to biological functions

Journal of Cellular Biochemistry

Volumn 115, Issue 5, 2014, Pages 812-818

  Jin, Guoxiang ^a   Gao, Yuan ^a,b   Lin, Hui Kuan ^a,b,c,d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d ASIA UNIVERSITY   (Taiwan)

Author keywords

CANCER; CYTOPLASMIC PML; TUMOR SUPPRESSOR

Indexed keywords

CYTOPLASM PROTEIN; CYTOPLASMIC PROMYELOCYTIC LEUKEMIA PROTEIN; MULTIPROTEIN COMPLEX; ONCOPROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; APOPTOSIS; ARTICLE; CALCIUM TRANSPORT; CELL AGING; CELL CYCLE PROGRESSION; CELL FUNCTION; CELL GROWTH; CELL NUCLEUS; CYTOPLASM; ENDOSOME; NUCLEAR EXPORT SIGNAL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

CANCER; CYTOPLASMIC PML; TUMOR SUPPRESSOR;

CARCINOGENESIS; CELL CYCLE PROTEINS; CELL NUCLEOLUS; CYTOPLASM; DNA DAMAGE; HUMANS; NUCLEAR PROTEINS; PROSPECTIVE STUDIES; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 84895552537     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24727     Document Type: Article

References (56)

1. Bellodi C,. 2006. Cytoplasmic function of mutant promyelocytic leukemia (PML) and PML-retinoic acid receptor. J Biol Chem 281: 14465-14473.
2. Bellodi C, Kindle K, Bernassola F, Cossarizza A, Dinsdale D, Melino G, Heery D, Salomoni P,. 2006. A cytoplasmic PML mutant inhibits p53 function. Cell Cycle 5: 2688-2692.
3. Bernardi R, Guernah I, Jin D, Grisendi S, Alimonti A, Teruya-Feldstein J, Cordon-Cardo C, Celeste Simon M, Rafii S, Pandolfi PP,. 2006. PML inhibits HIF-1α translation and neoangiogenesis through repression of mTOR. Nature 442: 779-785.
4. Borden KL, Campbell Dwyer EJ, Salvato MS,. 1998. An arenavirus RING (zinc-binding) protein binds the oncoprotein promyelocyte leukemia protein (PML) and relocates PML nuclear bodies to the cytoplasm. J Virol 72: 758-766.
5. Carracedo A, Ito K, Pandolfi PP,. 2011. The nuclear bodies inside out: PML conquers the cytoplasm. Curr Opin Cell Biol 23: 360-366.
6. Carracedo A, Weiss D, Leliaert AK, Bhasin M, de Boer VC, Laurent G, Adams AC, Sundvall M, Song SJ, Ito K, Finley LS, Egia A, Libermann T, Gerhart-Hines Z, Puigserver P, Haigis MC, Maratos-Flier E, Richardson AL, Schafer ZT, Pandolfi PP,. 2012. A metabolic prosurvival role for PML in breast cancer. J Clin Invest 122: 3088-3100.
7. Chan JY, Chin W, Liew CT, Chang KS, Johnson PJ,. 1998. Altered expression of the growth and transformation suppressor PML gene in human hepatocellular carcinomas and in hepatitis tissues. Eur J Cancer 34: 1015-1022.
8. Chaneton B, Gottlieb E,. 2012. Rocking cell metabolism: Revised functions of the key glycolytic regulator PKM2 in cancer. Trends Biochem Sci 37: 309-316.
9. Cheng X, Kao H-Y,. 2013. Post-translational modifications of PML: Consequences and implications. Front Oncol 2: 210. doi: 10.3389/fonc.2012.00210
10. Condemine W, Takahashi Y, Zhu J, Puvion-Dutilleul F, Guegan S, Janin A, de The H,. 2006. Characterization of endogenous human promyelocytic leukemia isoforms. Cancer Res 66: 6192-6198.
11. Cortes-Cros M, Hemmerlin C, Ferretti S, Zhang J, Gounarides JS, Yin H, Muller A, Haberkorn A, Chene P, Sellers WR, et al. 2013. M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth. Proc Natl Acad Sci USA 110: 489-494.
12. Cui W, Fowlis DJ, Bryson S, Duffie E, Ireland H, Balmain A, Akhurst RJ,. 1996. TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 86: 531-542.
13. Daniel MT, Koken M, Romagne O, Barbey S, Bazarbachi A, Stadler M, Guillemin MC, Degos L, Chomienne C, de The H,. 1993. PML protein expression in hematopoietic and acute promyelocytic leukemia cells. Blood 82: 1858-1867.
14. de The H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A,. 1991. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 66: 675-684.
15. Dellaire G,. 2006. Mitotic accumulations of PML protein contribute to the re-establishment of PML nuclear bodies in G1. J Cell Sci 119: 1034-1042.
16. Dellaire G, Bazett-Jones DP,. 2004. PML nuclear bodies: Dynamic sensors of DNA damage and cellular stress. Bioessays 26: 963-977.
17. Dellaire G, Ching RW, Dehghani H, Ren Y, Bazett-Jones DP,. 2006. The number of PML nuclear bodies increases in early S phase by a fission mechanism. J Cell Sci 119: 1026-1033.
18. Derynck R, Akhurst RJ, Balmain A,. 2001. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29: 117-129.
19. Dyck JA, Maul GG, Miller WH, Jr., Chen JD, Kakizuka A, Evans RM,. 1994. A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell 76: 333-343.
20. Fagioli M, Alcalay M, Pandolfi PP, Venturini L, Mencarelli A, Simeone A, Acampora D, Grignani F, Pelicci PG,. 1992. Alternative splicing of PML transcripts predicts coexpression of several carboxy-terminally different protein isoforms. Oncogene 7: 1083-1091.
21. Faresse N, Colland F, Ferrand N, Prunier C, Bourgeade MF, Atfi A,. 2008. Identification of PCTA, a TGIF antagonist that promotes PML function in TGF-beta signalling. EMBO J 27: 1804-1815.
22. Giorgi C, Ito K, Lin HK, Santangelo C, Wieckowski MR, Lebiedzinska M, Bononi A, Bonora M, Duszynski J, Bernardi R, et al. 2010. PML regulates apoptosis at endoplasmic reticulum by modulating calcium release. Science 330: 1247-1251.
23. Goddard AD, Borrow J, Freemont PS, Solomon E,. 1991. Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. Science 254: 1371-1374.
24. Goldberg MS, Sharp PA,. 2012. Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression. J Exp Med 209: 217-224.
25. Guo A, Salomoni P, Luo J, Shih A, Zhong S, Gu W, Pandolfi PP,. 2000. The function of PML in p53-dependent apoptosis. Nat Cell Biol 2: 730-736.
26. Gurrieri C,. 2004. Mutations of the PML tumor suppressor gene in acute promyelocytic leukemia. Blood 103: 2358-2362.
27. Houben F, De Vos WH, Krapels IP, Coorens M, Kierkels GJ, Kamps MA, Verstraeten VL, Marcelis CL, van den Wijngaard A, Ramaekers FC, et al. 2013. Cytoplasmic localization of PML particles in laminopathies. Histochem Cell Biol 139: 119-134.
28. Israelsen WJ, Dayton TL, Davidson SM, Fiske BP, Hosios AM, Bellinger G, Li J, Yu Y, Sasaki M, Horner JW, et al. 2013. PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell 155: 397-409.
29. Ito K, Carracedo A, Weiss D, Arai F, Ala U, Avigan DE, Schafer ZT, Evans RM, Suda T, Lee CH, et al. 2012. A PML-PPAR-delta pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance. Nat Med 18: 1350-1358.
30. Jakowlew SB,. 2006. Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev 25: 435-457.
31. Jensen K, Shiels C, Freemont PS,. 2001. PML protein isoforms and the RBCC/TRIM motif. Oncogene 20: 7223-7233.
32. Jin G, Wang YJ, Lin HK,. 2013. Emerging cellular functions of cytoplasmic PML. Front Oncol 3: 147.
33. Kakizuka A, Miller WH, Jr., Umesono K, Warrell RP, Jr., Frankel SR, Murty VV, Dmitrovsky E, Evans RM,. 1991. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 66: 663-674.
34. Kastner P, Perez A, Lutz Y, Rochette-Egly C, Gaub MP, Durand B, Lanotte M, Berger R, Chambon P,. 1992. Structure, localization and transcriptional properties of two classes of retinoic acid receptor alpha fusion proteins in acute promyelocytic leukemia (APL): Structural similarities with a new family of oncoproteins. EMBO J 11: 629-642.
35. Katakura Y, Nakata E, Miura T, Shirahata S,. 1999. Transforming growth factor beta triggers two independent-senescence programs in cancer cells. Biochem Biophys Res Commun 255: 110-115.
36. Kentsis A, Dwyer EC, Perez JM, Sharma M, Chen A, Pan ZQ, Borden KL,. 2001. The RING domains of the promyelocytic leukemia protein PML and the arenaviral protein Z repress translation by directly inhibiting translation initiation factor eIF4E. J Mol Biol 312: 609-623.
37. Lin HK, Bergmann S, Pandolfi PP,. 2004. Cytoplasmic PML function in TGF-beta signalling. Nature 431: 205-211.
38. Lin DY, Huang YS, Jeng JC, Kuo HY, Chang CC, Chao TT, Ho CC, Chen YC, Lin TP, Fang HI, et al. 2006. Role of SUMO-interacting motif in Daxx SUMO modification, subnuclear localization, and repression of sumoylated transcription factors. Mol Cell 24: 341-354.
39. Martin N, Benhamed M, Nacerddine K, Demarque MD, van Lohuizen M, Dejean A, Bischof O,. 2012. Physical and functional interaction between PML and TBX2 in the establishment of cellular senescence. EMBO J 31: 95-109.
40. Mathews V, George B, Chendamarai E, Lakshmi KM, Desire S, Balasubramanian P, Viswabandya A, Thirugnanam R, Abraham A, Shaji RV, et al. 2010. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: Long-term follow-up data. J Clin Oncol 28: 3866-3871.
41. Mazurek S,. 2011. Pyruvate kinase type M2: A key regulator of the metabolic budget system in tumor cells. Int J Biochem Cell Biol 43: 969-980.
42. McNally BA, Trgovcich J, Maul GG, Liu Y, Zheng P,. 2008. A role for cytoplasmic PML in cellular resistance to viral infection. PLoS ONE 3: e2277.
43. Pandolfi PP, Grignani F, Alcalay M, Mencarelli A, Biondi A, LoCoco F, Pelicci PG,. 1991. Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties. Oncogene 6: 1285-1292.
44. Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S, Higashimoto Y, Appella E, Minucci S, Pandolfi PP, et al. 2000. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 406: 207-210.
45. Reymond A, Meroni G, Fantozzi A, Merla G, Cairo S, Luzi L, Riganelli D, Zanaria E, Messali S, Cainarca S, et al. 2001. The tripartite motif family identifies cell compartments. EMBO J 20: 2140-2151.
46. Schafer ZT, Grassian AR, Song L, Jiang Z, Gerhart-Hines Z, Irie HY, Gao S, Puigserver P, Brugge JS,. 2009. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 461: 109-113.
47. Seo SR, Ferrand N, Faresse N, Prunier C, Abecassis L, Pessah M, Bourgeade MF, Atfi A,. 2006. Nuclear retention of the tumor suppressor cPML by the homeodomain protein TGIF restricts TGF-beta signaling. Mol Cell 23: 547-559.
48. Shimada N, Shinagawa T, Ishii S,. 2008. Modulation of M2-type pyruvate kinase activity by the cytoplasmic PML tumor suppressor protein. Genes Cells 13: 245-254.
49. Siegel PM, Massague J,. 2003. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 3: 807-821.
50. Terris B, Baldin V, Dubois S, Degott C, Flejou JF, Henin D, Dejean A,. 1995. PML nuclear bodies are general targets for inflammation and cell proliferation. Cancer Res 55: 1590-1597.
51. Turelli P, Doucas V, Craig E, Mangeat B, Klages N, Evans R, Kalpana G, Trono D,. 2001. Cytoplasmic recruitment of INI1 and PML on incoming HIV preintegration complexes: Interference with early steps of viral replication. Mol Cell 7: 1245-1254.
52. Vernier M, Bourdeau V, Gaumont-Leclerc MF, Moiseeva O, Begin V, Saad F, Mes-Masson AM, Ferbeyre G,. 2011. Regulation of E2Fs and senescence by PML nuclear bodies. Genes Dev 25: 41-50.
53. Weis K, Rambaud S, Lavau C, Jansen J, Carvalho T, Carmo-Fonseca M, Lamond A, Dejean A,. 1994. Retinoic acid regulates aberrant nuclear localization of PML-RAR alpha in acute promyelocytic leukemia cells. Cell 76: 345-356.
54. Zaugg K, Yao Y, Reilly PT, Kannan K, Kiarash R, Mason J, Huang P, Sawyer SK, Fuerth B, Faubert B, et al. 2011. Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. Genes Dev 25: 1041-1051.
55. Zheng P, Guo Y, Niu Q, Levy DE, Dyck JA, Lu S, Sheiman LA, Liu Y,. 1998. Proto-oncogene PML controls genes devoted to MHC class I antigen presentation. Nature 396: 373-376.
56. Zhu J, Koken MH, Quignon F, Chelbi-Alix MK, Degos L, Wang ZY, Chen Z, de The H,. 1997. Arsenic-induced PML targeting onto nuclear bodies: Implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci USA 94: 3978-3983.